COVID-19 and NTD innovation

Phil Downs, October 2020
A man wearing a mask gives a demonstration to distributors in a school classroom.

When COVID-19 established its foothold in Africa in April 2020, the World Health Organization (WHO) issued interim guidance encouraging neglected tropical disease (NTD) elimination programmes to pause community-based activities, including mass drug administration (MDA) campaigns.

At Sightsavers, we knew that pausing MDA could undo the gains made in the fight against NTDs. Hence, collaborating with donors and partners, we reacted swiftly to adapt a WHO risk assessment tool for the context of NTDs. The new risk assessment and mitigation action tool, known as RAMA, has enabled us and government partners to mitigate the risk of spreading COVID-19 and restart treatment.

The prospect of pausing our MDA work indefinitely was particularly concerning because the delivery of millions of preventative treatments annually is not just important at a moment in time, it builds on past efforts and is critical to present and future efforts towards elimination of a disease. Miss out on a year of treatment, and you might significantly delay when the disease is eliminated and allow for new cases to emerge.

Yet faced with these unprecedented circumstances, there was a collective effort to take stock of where countries stood and to find a way to move forward safely – sometimes surprisingly quickly – once governments completed their risk-benefit assessments and determined which activities could resume. With our regular and new partners, we began to investigate processes and tools that could objectively mitigate the risk of spreading COVID-19 in our outreach work and actively contribute to fighting the spread of COVID-19. For example, using our knowledge and expertise we were able to flex our largest NTD programme, Ascend West and Central Africa, to help combat COVID-19. Technical in nature, but monumental in impact, the unassumingly named Excel sheet-based RAMA tools are likely to have an impact on MDA and outreach work for years to come.

“Technical in nature, but monumental in impact, the RAMA tools are likely to have an impact on mass drug administration and outreach work for years to come.”

Two people washing their hands outside.
A distributor washes her hands before delivering medicine in Jigawa, Nigeria.

The RAMA suite of tools are an adaptation of a risk assessment tool the WHO created for mass religious gatherings. This, in turn, had followed a recommended framework for conducting rapid risk assessment of acute public health events.

Three separate tools translated into French and English, the RAMA tools include one for treatment distribution, a second for disease specific surveys, and a third for case finding and surgical outreach for trichiasis and hydrocele.

Each tool sets out a rigorous set of questions to be answered by regional technical teams and ministries of health. They are asked to identify risk factors, consider how routine activities are to be adapted and review the financial implications of working in a different way. Sightsavers has adopted the tools as part of a larger internal review process, which in part provides a formal mechanism between government and projects to continue to monitor the COVID-19 trends in the specific area under consideration. Following a final review by our NTD senior management team, signoff is given if all the requirements to resuming outreach work have been met.

Each tool not only allows government and partners to rigorously assess and restart critical outreach work as soon as safe to do so, as we have already done for MDA in the Nigerian state of Jigawa through the Accelerate Project, but it has the potential to be applied to other situations such as regional conflict or outbreaks of other diseases such as cholera.

Such an approach complements our overall aim to strengthen health systems, build resilience, and facilitate integration and cross-sector collaboration. It provides opportunities to strengthen integrated disease surveillance, improve the capacity of local supervisors to manage public health interventions, and facilitate the introduction of electronic data capture platforms to assist supervisors in ensuring what is planned is actually implemented.

As we work to help reinstate government-led NTD programmes, the opportunity is there to be even more innovative. While we fight COVID-19 and aim to preserve NTD gains, there is potential to accelerate the interruption of NTDs, improve the quality of service delivery, and shorten the time frame for achieving elimination.

The RAMA suite of tools and associated documents will soon be available to access via our forthcoming open data resource portal.


Phil DownsPhil Downs is Sightsavers’ Technical Director for neglected tropical diseases.

A man washes his hands.

Helping the fight against COVID-19

Ron Bannerman, director of Ascend West and Central Africa, explains how Sightsavers and its partners are using their expertise to help countries combat the pandemic, while ensuring they preserve the gains made in their fight against neglected tropical diseases.

Read more

Read about Sightsavers’ work with NTDs

Find out more

More from our
Neglected Tropical Disease work

A female community drug distributor measures a girl to see how much medication she needs to protect her from trachoma.
Sightsavers from the field

“Our programme has transformed communities”

Now in its sixth year, the Accelerate programme has already delivered 53 million treatments to protect people from trachoma, and managed 91,000 advanced cases of the disease.

March 2024
Eye care staff perform trachoma surveys on children in Cote D'Ivoire.

Sightsavers’ Accelerate programme gets US$36.5 million funding boost to banish trachoma

The extra funding from international donors will help speed up the elimination of trachoma in Africa by expanding and extending the programme.

March 2024
Dr Ndalela examines a boy's eyes and applies ointment to ease the symptoms of trachoma.

Sightsavers awarded grant to help eliminate trachoma in Zambia

The Leona M. and Harry B. Helmsley Charitable Trust has awarded Sightsavers a grant of US$2.19 million to help fight the disease.

January 2024